Regeneron的库存量在2025年至今下降了46%, Regeneron's stock dropped 46% year-to-date in 2025 after mixed COPD trial results raised pipeline concerns.

Regenenron制药公司的股票在2025年第二季度下降,9月下降2.89%,去年下降46.36%,9月26日下降563.90美元。 Regeneron Pharmaceuticals' stock fell in the second quarter of 2025, declining 2.89% in September and 46.36% over the past year, closing at $563.90 on September 26. 这一下降是在其药物伊替基单抗的一项关键慢性阻塞性肺病试验结果好坏参半之后进行的，两项试验中只有一项达到预期。 The drop followed mixed results from a key COPD trial for its drug itepekimab, with only one of two trials meeting expectations. 尽管从与关税有关的损失中较广泛的市场复苏,投资者对输油管的不确定性和临床结果越来越关切,这导致业绩不佳,特别是Baird Chautauqua International和全球增长基金等主要持有人的表现不佳。 Despite broader market recovery from tariff-related losses, investor concerns grew over pipeline uncertainty and clinical outcomes, contributing to underperformance, particularly for major holders like the Baird Chautauqua International and Global Growth Fund.